8 research outputs found
The effects and safety of PD‐1/PD‐L1 inhibitors on head and neck cancer: A systematic review and meta‐analysis
Recommended from our members
Genomic sequencing and precision medicine in head and neck cancers
Head and neck squamous cell carcinoma (HNSCC) remains a common and deadly disease. Historically, surgical and chemoradiation treatments have been met with modest success, and understanding of genetic drivers of HNSCC has been limited. With recent next generation sequencing studies focused on HNSCC, we are beginning to understand the genetic landscape of HNSCCs and are starting to identify and advance targeted options for patients. In this review, we describe current knowledge and recent advances in sequencing studies of HNSCC, discuss current limitations and future directions for further genomic analysis, and highlight the translational advances being undertaken to treat this important disease
Risk of second primary cancer in oral squamous cell carcinoma
Abstract
Background: The incidence and survival of oral squamous cell carcinoma (OSCC) patients have increased in recent years. Understanding their long‐term survival aspects is essential for optimal treatment and follow‐up planning. Almost one in five cancers diagnosed occurs nowadays in individuals with a previous diagnosis of cancer.
Methods: Patients diagnosed with primary OSCC during 1953‐2015 were retrieved from the Finnish Cancer Registry. Both standardized incidence ratios (SIR) and excess absolute risk (EAR) per 1000 person‐years at risk (PYR) of second primary cancer (SPC) were calculated relative to the general population.
Results: Among 6602 first primary OSCC patients there were 640 (10%) SPCs. The SIR for SPCs was 1.85 (95% CI: 1.71‐1.99, P < .001) corresponding to an EAR of 8.78 (95% CI: 7.29‐10.26).
Conclusions: Health care professionals should be aware of the second primary cancer risk after management of primary OSCC and patients need to be counseled about this phenomenon